Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
about
[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
P2860
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@en
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@nl
type
label
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@en
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@nl
prefLabel
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@en
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines.
@nl
P2093
P2860
P50
P1476
Trastuzumab emtansine delays a ...... NSCLC EGFR mutated cell lines
@en
P2093
Andrea Cavazzoni
Claudia Fumarola
Daniele Cretella
Elisabetta Barocelli
Graziana Digiacomo
Lisa Flammini
Mara Bonelli
Nadia Naldi
Pier Giorgio Petronini
Silvia La Monica
P2860
P2888
P356
10.1186/S13046-017-0653-7
P577
2017-12-04T00:00:00Z
P6179
1093162848